Simulations Plus (NASDAQ:SLP) Updates FY 2025 Earnings Guidance

Key Points

• Simulations Plus updated its FY 2025 earnings guidance, projecting earnings per share (EPS) of $1.030, exceeding the consensus estimate of $0.990, along with revenue guidance of $79.1 million compared to an estimated $78.3 million.
• The company's stock opened at $15.56, with a fifty-two week trading range between $12.39 and $37.67 and a market cap of $313.22 million.
• Brokerage analysts have mixed ratings with four "Buy," five "Hold," and one "Sell" rating, while the average target price stands at $24.40.

Simulations Plus (NASDAQ:SLP - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.030-1.030 for the period, compared to the consensus earnings per share estimate of 0.990. The company issued revenue guidance of $79.1 million-$79.1 million, compared to the consensus revenue estimate of $78.3 million. Simulations Plus also updated its FY 2026 guidance to 1.030-1.100 EPS.

Simulations Plus Stock Performance

Shares of NASDAQ SLP opened at $15.56 on Wednesday. Simulations Plus has a fifty-two week low of $12.39 and a fifty-two week high of $37.67. The stock has a market cap of $313.22 million, a price-to-earnings ratio of -4.94 and a beta of 0.99. The firm's 50-day simple moving average is $14.89 and its 200 day simple moving average is $20.65.

Wall Street Analyst Weigh In

Several equities analysts have commented on SLP shares. BTIG Research dropped their target price on shares of Simulations Plus from $41.00 to $25.00 and set a "buy" rating on the stock in a research report on Monday, July 7th. TD Cowen started coverage on shares of Simulations Plus in a research report on Tuesday, September 30th. They set a "hold" rating and a $16.00 target price on the stock. Cowen started coverage on shares of Simulations Plus in a research report on Tuesday, September 30th. They set a "hold" rating on the stock. Zacks Research raised shares of Simulations Plus to a "hold" rating in a research report on Tuesday, August 12th. Finally, KeyCorp cut shares of Simulations Plus from an "overweight" rating to a "sector weight" rating in a research report on Tuesday, July 15th. Four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $24.40.

Institutional Investors Weigh In On Simulations Plus

Several large investors have recently modified their holdings of the stock. Royal Bank of Canada grew its stake in Simulations Plus by 26.6% in the 1st quarter. Royal Bank of Canada now owns 114,885 shares of the technology company's stock valued at $2,817,000 after buying an additional 24,132 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Simulations Plus by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company's stock valued at $233,000 after acquiring an additional 390 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Simulations Plus during the 1st quarter valued at $255,000. Woodline Partners LP raised its holdings in Simulations Plus by 32.1% during the 1st quarter. Woodline Partners LP now owns 13,239 shares of the technology company's stock valued at $325,000 after acquiring an additional 3,220 shares during the period. Finally, Rhumbline Advisers raised its holdings in Simulations Plus by 12.2% during the 2nd quarter. Rhumbline Advisers now owns 74,325 shares of the technology company's stock valued at $1,297,000 after acquiring an additional 8,103 shares during the period. Hedge funds and other institutional investors own 78.08% of the company's stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.